CardiaTecAI-driven Multi-Omics Drug Discovery
CardiaTec offers validated drug candidates for the treatment of Coronary Artery Disease/Acute Coronary Syndrome (CAD/ACS). CardiaTec’s proprietary ML architecture integrates information from scientific literature, structured databases and proprietary dataset derived from ACS-specific multi-omic analysis to generate drug targets. Pharma and biotech customers use these targets to develop novel therapeutics or repurpose drugs.
Dr. Namshik Han, Raphael Peralta, Thelma Zablocki
Laidlaw Scholars Ventures, O2H Ventures, Cambridge Enterprise
AI, Multi-Omics, Drug Development